… Navitoclax is an inhibitor of BCL-XL, which is a potential anti-cancer … BCL-XL degrader
DT2216 (navitoclax fused to a VHL-… a safe and effective first-in-class anticancer agent targeting …

… degrader that retards cellular proliferation and induces apoptosis in multiple cancer cell lines.
Selective STAT3 depletion was achieved over … , a BCL-XL targeting PROTAC that engages …

… , high doses are required to achieve biological activity in vivo, which … Bcl-2, Mcl-1 and Bcl-xL,
is a vital reason for tumor cells to … the PROTAC strategy has a powerful ability to degrade …

… of an orally active PROTAC AR degrader for the treatment of … , the design of PROTAC degraders
to achieve excellent oral … strategies toward discovering potent PROTAC degraders of AR …

… a PG (12)-based PROTAC, SJ10542, with highly selective JAK … a selective degrader of
HDAC3 with a submicromolar activity … 31 showed a powerful anticancer activity in breast, ovarian, …

… Here, we report the use of PROTAC technology to reduce … and synthesized a series of
Bcl-xl-Ps that target Bcl-xl to CRBN for … to degrade Bcl-xl and selectively induce IR-SC apoptosis. …

… We and others previously reported the link of Bcl-xL protein … a Bcl-xL proteolysis-targeting
chimera (PROTAC) that targets … have potent in vitro proliferation inhibitory effect and to achieve …

… protein degradation achieved by a specific PROTAC molecule … In a SW620 xenograft
model, 4 displayed potent antitumor … inhibitor into a selective/specific PROTAC degrader. This …

… binder but still achieve a high degree of selective degradation. One of … degraded by VHL
PROTAC 8, 14 kinases were degraded by cereblon PROTAC 9, and 6 kinases were degraded …

… Here, we develop a peptide-based PROTAC, which achieves the purpose of degrading
FOXM1 by facilitating the recruitment of E3 ubiquitin to FOXM1. Phage display technology was …